Robin Mansukhani

Robin Mansukhani is the CEO and Co-Founder of Deciduous Therapeutics, a venture-backed biotech pioneering novel immunotherapies to treat age-related diseases, including fibrosis. Under his leadership, Deciduous is advancing a new class of antifibrotic therapies aimed at reprogramming the immune system to selectively eliminate pathogenic senescent cells implicated in IPF and other chronic diseases. Robin previously co-founded and served as CEO of Alzeca Biosciences and has advised early-stage biotech companies in the aging and CNS space. He holds a B.S. in Biochemistry from Case Western Reserve University and has spoken at leading forums including TEDx.